Akari Therapeutics
AKTX
12 hedge funds and large institutions have $15.1M invested in Akari Therapeutics in 2017 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 3 closing their positions.
4% more capital invested
Capital invested by funds: $14.5M → $15.1M (+$650K)
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
1.46% less ownership
Funds ownership: 6.64% → 5.18% (-1.5%)
14% less funds holding
Funds holding: 14 → 12 (-2)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HP
Hikari Power
Tokyo,
Japan
|
+$427K |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$60K |
| 3 |
Morgan Stanley
New York
|
+$41.2K |
| 4 |
HNB
Huntington National Bank
Columbus,
Ohio
|
+$37.5K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$18.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$1.8M |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
-$855K |
| 3 |
QF
QVT Financial
New York
|
-$531K |
| 4 |
Millennium Management
New York
|
-$465K |
| 5 |
AG
Advisor Group
Phoenix,
Arizona
|
-$30K |
AKTX Hedge Fund Activity: Q3 2017 in Review
12 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Akari Therapeutics (AKTX) for Q3 2017, worth a combined $15.1M — up 4.5% from $14.5M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of AKTX and 2 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 3 added.
The largest buyer was Hikari Power, adding an estimated $427K. The largest seller was Deerfield Management, cutting an estimated $1.8M.
- 12 institutional investors held Akari Therapeutics (AKTX) as of Q3 2017, down from 14 in Q2 2017.
- Funds reported $15.1M of Akari Therapeutics stock for Q3 2017, up 4.5% quarter-over-quarter.
- 2 funds opened new Akari Therapeutics positions in Q3 2017 and 3 closed out, a net change of -1 holder.
- The largest Akari Therapeutics buyer in Q3 2017 was Hikari Power, an estimated $427K added.
- The largest Akari Therapeutics seller in Q3 2017 was Deerfield Management, an estimated $1.8M sold.
Based on aggregated 13F filings for Q3 2017.